Real‐life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria

Abstract

Patients with severe allergic asthma above recommended dosing criteria for omalizumab have significantly improved symptom control, quality of life and lung function to a similar degree to within-range participants, achieved without dose escalation above 750 mg.